Allarity Therapeutics, Inc. (ALLR)
$0.248
Rating:
Recommendation:
-
| Symbol | ALLR |
|---|---|
| Price | $0.248 |
| Beta | -0.003 |
| Volume Avg. | 2.12M |
| Market Cap | 3.578M |
| Shares () | - |
| 52 Week Range | 0.2-9.219 |
| 1y Target Est | - |
| DCF Unlevered | ALLR DCF -> | |
|---|---|---|
| DCF Levered | ALLR LDCF -> | |
| ROE | -173.30% | Strong Sell |
| ROA | -106.53% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 417.67% | Strong Buy |
| P/E | - | |
| P/B | 0.70 | Buy |
Latest ALLR news
About
Download (Excel)Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.